Bionano Genomics, Inc. (BNGO) Stock Price & Analysis
Bionano Genomics, Inc. (BNGO) fell 0.85% to USD 1.16 as of June 10, 2026 at 02:03 UTC, according to Nexqual real-time market data.
BNGO last closed at USD 1.17; the session ranged USD 1.16–1.24 on volume of 218,457 shares. Market capitalization is $13.31M, with a 52-week range of USD 1.06–5.5 (NCM). Source: Nexqual, June 10, 2026 at 02:03 UTC.
Key Statistics (as of June 10, 2026 at 02:03 UTC)
| Price | USD 1.16 |
|---|---|
| Change | ▼ 0.85% (down) |
| Previous Close | USD 1.17 |
| Open | USD 1.2 |
| Day Range | USD 1.16 – 1.24 |
| 52-Week Range | USD 1.06 – 5.5 |
| Volume | 218,457 shares |
| Market Cap | $13.31M |
| Exchange | NCM |
Technical Analysis (BNGO)
Nexqual's technical model rates BNGO "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:03 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.04 (neutral) |
| vs SMA50 | Below (USD 1.22) |
| MACD | -0.01 (negative) |
Analyst Ratings (BNGO)
Wall Street analysts rate BNGO "Strong Buy" based on 2 analysts, with a mean price target of USD 5 (range USD 4–6), per Nexqual as of June 10, 2026 at 02:03 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 5 |
| High Target | USD 6 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (BNGO)
| Next Earnings Date | 2026-08-13 |
|---|---|
| Revenue Estimate | $7.48M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.75 vs est -0.95 ▲ beat |
| 2025-12-31 | USD -0.03 vs est -4.14 ▲ beat |
| 2025-09-30 | USD -1.59 vs est -2.34 ▲ beat |
| 2025-06-30 | USD -1.97 vs est -2.99 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:03 UTC.
Financials & Fundamentals (BNGO)
| Total Revenue | $28.74M |
|---|---|
| Revenue Growth (YoY) | +3.60% |
| Gross Margin | +46.97% |
| Operating Margin | -118.09% |
| Profit Margin | -109.95% |
| ROE | -73.78% |
| Debt / Equity | 45.42 |
| Current Ratio | 1.84 |
| Total Cash | $14.40M |
| Total Debt | $17.01M |
| Free Cash Flow | $-5.73M |
Source: Nexqual, June 10, 2026 at 02:03 UTC.
Financial Health Score (BNGO)
Nexqual rates Bionano Genomics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:03 UTC.
| Growth | Weak — Revenue -7% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $14M cash vs $17M debt |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Critical — ROE -74%, ROA -28.6% |
Ownership (BNGO)
| Insider Ownership | +7.40% |
|---|---|
| Institutional Ownership | +10.12% |
| Shares Outstanding | 11.47M |
| Float | 10.30M |
| Short % of Float | +9.79% |
Source: Nexqual, June 10, 2026 at 02:03 UTC.
Leadership (BNGO)
Bionano Genomics, Inc. is led by Albert A. Luderer (age 76), Chairman, Interim CEO, Interim President & Interim Principal Financial Officer, per Nexqual as of June 10, 2026 at 02:03 UTC.
| Chairman, Interim CEO, Interim President & Interim Principal Financial Officer | Albert A. Luderer (age 76) |
|---|---|
| Chief Operating Officer | Mark Oldakowski (age 51) |
Major Backers & Investors (BNGO)
Notable institutional backers of Bionano Genomics, Inc. include GSA Capital Partners LLP, Fidelity, Carret Asset Management, LLC, according to Nexqual as of June 10, 2026 at 02:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| GSA Capital Partners LLP | 3.08% |
| Fidelity | 1.29% |
| Carret Asset Management, LLC | 0.61% |
| Renaissance Technologies | 0.42% |
| Prudential Financial, Inc. | 0.24% |
| Two Sigma Securities, LLC | 0.16% |
| Virtu Financial LLC | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.63% |
| Geode Capital | 1.46% |
| Northern Trust | 0.18% |
Source: Nexqual, June 10, 2026 at 02:03 UTC.
From Bionano Genomics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia.
- The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
- In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NNDM | Nano Dimension Ltd. | USD 1.49 | ▼ 4.49% |
| SENS | Senseonics Holdings, Inc. | USD 7.43 | ▲ 11.39% |
| OCGN | Ocugen, Inc. | USD 1.24 | ▼ 3.13% |
| GEVO | Gevo, Inc. | USD 1.5 | ▼ 7.98% |
| SNDL | SNDL Inc. | USD 1.46 | ▲ 2.82% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:03 UTC. This page is informational and not investment advice.